Bank Of New York Mellon Corp Prelude Therapeutics Inc Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.61 - $8.5 $133,132 - $245,471	28,879 New	28,879 $174,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $50 - $88	-10 Reduced 0.03%	29,179 $193,000
Q2 2022 Aug 15, 2022	SELL	$4.0 - $7.55 $122,524 - $231,264	-30,631 Reduced 51.21%	29,189 $153,000
Q1 2022 May 11, 2022	BUY	$6.9 - $13.22 $14,793 - $28,343	2,144 Added 3.72%	59,820 $412,000
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $277,797 - $741,573	23,364 Added 68.09%	57,676 $718,000
Q3 2021 Nov 12, 2021	BUY	$25.78 - $38.65 $104,615 - $156,841	4,058 Added 13.41%	34,312 $1.07 Million
Q2 2021 Aug 11, 2021	SELL	$28.63 - $44.3 $22,388 - $34,642	-782 Reduced 2.52%	30,254 $866,000
Q1 2021 May 13, 2021	BUY	$39.27 - $91.68 $2,474 - $5,775	63 Added 0.2%	31,036 $1.34 Million
Q4 2020 Feb 09, 2021	BUY	$28.81 - $88.94 $892,332 - $2.75 Million	30,973 New	30,973 $2.22 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.9M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.